Polynovo vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Polynovo (PNV) and Abbott Laboratories (ABT) compare, as of Aug 15, 2026.
As of Aug 15, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Polynovo trades at A$0.97 versus a fair value of A$0.32 (-67%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).
Polynovo
PNV.AU · AUD · Health Care
-67%
upside to fair value
overvalued
PriceA$0.97
Fair ValueA$0.32
Quality54/100
Abbott Laboratories
ABT · USD · Health Care
-33%
upside to fair value
overvalued
Price$111
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
PolynovoAbbott Laboratories
Valuation
94.7×P/E (TTM)27.7×
3.63×P/S (TTM)3.89×
6.08×P/B3.36×
71.5×EV/EBITDA15.1×
1.53×PEG1.47×
Profitability
7%Net margin14%
3%Operating margin13%
12%Return on equity12%
2%Return on assets6%
Growth
18%Revenue growth (YoY)8%
45.3%Avg. growth/yr (3Y)0.5%
41.8%Avg. growth/yr (5Y)5.1%
Balance & size
0.03×Debt / equity0.19×
$506MMarket cap$175B
mixedGrowth qualityhealthy
Abbott Laboratories leads: 6 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Polynovoof which business quality 56 · market factors 25Abbott Laboratoriesof which business quality 66 · market factors 55
ProfitabilityMargins and returns on capital today
70
50
Quality GrowthAre margins and returns improving?
84
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
17
65
Low VolatilityCalm price path (market factor)
21
83
MomentumPrice trend over the last 3–12 months (market factor)
35
45
52W MomentumDistance to the 52-week high (market factor)
13
38
Net IssuanceBuybacks instead of dilution
73
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Polynovo
DCF ModelsA$0.15
Earnings-BasedA$0.67
MultiplesA$0.27
Asset-BasedA$0.08
Economic ProfitA$0.13
Growth EarningsA$0.89
15 of 15 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Polynovo
Bear A$0.24Fair Value A$0.32Bull A$0.40
A$0.97 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$111 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Polynovo · Health Care
Quality score54 · above median
Fair value upside-67% · bottom 25%
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-33% · below median
Bottom line
As of Aug 15, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Polynovo trades at A$0.97 versus a fair value of A$0.32 (-67%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
